Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 62059

Name: National Advisory Council on 

Nurse Education and Practice (NACNEP). 

Dates and Times: November 3, 2004, 8:30 

a.m.–5 p.m.; November 4, 2004, 8:30 a.m.–5 

p.m.; November 5, 2004, 8:30 a.m.–3 p.m. 

Place: The St. Regis Hotel, 923 16th Street, 

NW., Washington, DC 20006. 

Status: The meeting will be open to the 

public. 

Agenda: Agency and Bureau 

administrative updates will be provided. The 

purpose of the meeting is to continue the 

April 2004 meeting focusing on geriatrics 

with implications for the nursing workforce, 

education and practice. While the April 

meeting focused on geriatric nursing 

workforce issues, geriatric nursing practice 

and education will be highlighted in this 

meeting. An opening presentation will 

provide a comprehensive view of patient 

safety in long-term care to be followed by a 

panel presentation of Health Resources and 

Services Administration, Bureau of Health 

Professions (BHPr), geriatric exemplars. 

Additional presentations will highlight 

culturally competent care from the 

consumers’ perspective and geriatric nursing 

education addressing models, gaps and 

implications for the future. An update of 

BHPr’s performance measures will also be 

presented. Work group discussions will take 

place on the first and second days to develop 

recommendations related to geriatrics. On the 

third day the Council will review a draft of 

the Fourth Report to the Secretary, HHS, and 

Congress and finalize all geriatrics 

recommendations from the April 2004 and 

the November 2004 meetings on nursing 

workforce, education and practice.

FOR FURTHER INFORMATION CONTACT:

Anyone interested in obtaining a roster 

of members, minutes of the meeting, or 

other relevant information should write 

or contact Ms. Elaine G. Cohen, M.S., 

R.N., Executive Secretary, National 

Advisory Council on Nurse Education 

and Practice, Parklawn Building, Room 

9–35, 5600 Fishers Lane, Rockville, 

Maryland 20857, telephone (301) 443–

1405.

Dated: October 14, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–23627 Filed 10–21–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: (301) 

496–7057; fax: (301) 402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Inhibitors of HIV Ribonuclease H 

Antiviral Properties 

Drs. John Beutler, Stuart LeGrice, Scott 

Budihas, Antony Wamiru, Roberta 

Gardella, and Jennifer Wilson (all of 

NCI); Dr. Michael Parniak (EM) 

U.S. Provisional Application filed 30 

Aug 2004 (DHHS Reference No. E–

256–2004/0–US–01)

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

The invention describes a class of 

compounds that inhibit HIV RNase H 

and the methods of using these 

compounds for the treatment of HIV 

infections. More specifically, these 

compounds are vinylogous urea 

derivative containing substituted 

thiophene core structures and these 

compounds were part of the 100,000 

member library of compounds 

purchased by NCI from ChemBridge. 

The selectivity of the antiviral activity 

was demonstrated in their selective 

inhibition of HIV–1 and HIV–2 Rnase H 

enzymes 1 in the CEM cell line of CD4+ 

lymphoblast cells. Five members of this 

class of compounds were able to block 

the cytopathic effect of the virus at 

concentrations that did not inhibit cell 

growth. Thus, these compounds may be 

used in the development of therapeutics 

for the treatment of retroviral infections, 

such as AIDS. In addition, these 

compounds described in this invention 

may also have particular value when 

used in combination treatments with 

other antiviral therapies directed at 

other viral targets, such as protease and 

integrase.

Protozoan Derived Antagonist of CCR5 

Drs. Alan Sher, Julio Aliberti, Jose 

Ribeiro, and John Andersen (all of 

NIAID); Dr. Hana Golding (FDA) 

U.S. Provisional Application No. 60/

586,884 filed 08 Jul 2004 (DHHS 

Reference No. E–272–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

The invention describes the anti-HIV 

properties of cyclophilin-18, a protein 

expressed by the protozoan parasite 

Toxoplasma gondii. The protein was 

found to bind to the chemokine receptor 

CCR5 which is also a co-receptor for the 

HIV virus. Both the native and 

recombinant molecules display 

inhibitory activity in HIV–1 fusion 

(syncitia formation) and infectivity 

assays with human T cells and 

macrophages. Thus, Toxoplasma gondii 

cyclophilin-18 or modified versions of 

the molecule may be used in the 

development of treatment for AIDS. In 

particular, the protein described in this 

invention may have particular value 

when used as a microbicide for blocking 

initial HIV infection. More details of 

this invention can be found in Golding 

et al., ‘‘Inhibition of HIV–1 Infection by 

a CCR5 Binding Cyclophilin from 

Toxoplasma gondii’’, Blood 1 Nov 2003 

102(9): 3280–3286. 

Treatment of Human Viral Infections 

(Resveratrol) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

588,013 filed 13 Jul 2004 (DHHS 

Reference No. E–279–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

an Egr 1 activator called Resveratrol (3, 

5, 4’’-trihydroxystilbene) and its 

derivatives. It has been known that HIV, 

once it infects a cell, integrates into the 

cellular genome and can (1) rapidly 

undergo lytic infection, or (2) lay 

dormant for a period of time (latent 

infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since Resveratrol 

and its derivatives can activate lytic 

replication from latent infected cells via 

its effects on Erk1/2 signaling, 

Resveratrol and its derivatives may lead 

to therapies in which Resveratrol and/

or its derivatives is given together with 

highly active antiretroviral therapy in an 

62060 Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 

effort to decrease or eliminate the 

reservoir of latent infected cells with 

hope of perhaps eventually curing a 

patient of HIV infection. 

Treatment of Human Viral Infections 

(Proteosome Inhibitors) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

587,810 filed 13 Jul 2004 (DHHS 

Reference No. E–280–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

proteosome inhibitors and their 

derivatives. It has been known that HIV, 

once it infects a cell, integrates into the 

cellular genome and can (1) rapidly 

undergo lytic infection, or (2) lay 

dormant for a period of time (latent 

infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since proteosome 

inhibitors can activate lytic replication 

from latent infected cells, proteosome 

inhibitors may lead to therapies in 

which proteosome inhibitors are given 

together with highly active antiretroviral 

therapy in an effort to decrease or 

eliminate the reservoir of latent infected 

cells with hope of perhaps eventually 

curing a patient of HIV infection. 

Treatment of Human Viral Infections 

(Imatinib) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

588,015 filed 13 Jul 2004 (DHHS 

Reference No. E–281–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

abl-kinase inhibitor called imatinib and 

its derivatives. It has been known that 

HIV, once it infects a cell, integrates into 

the cellular genome and can (1) rapidly 

undergo lytic infection, or (2) lay 

dormant for a period of time (latent 

infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since imatinib and 

its derivatives can activate lytic 

replication from latent infected cells by 

activating NF–kB, imatinib and its 

derivatives may lead to therapies in 

which imatinib and/or its derivatives is 

given together with highly active 

antiretroviral therapy in an effort to 

decrease or eliminate the reservoir of 

latent infected cells with hope of 

perhaps eventually curing a patient of 

HIV infection. 

Treatment of Human Viral Infections 

(Farnesyl Transferase Inhibitors) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

587,771 filed 13 Jul 2004 (DHHS 

Reference No. E–282–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

farnesyl transferase inhibitors such as 

FTI277, L–744832, BMS214662, 

R115777 and SCH66336. It has been 

known that HIV, once it infects a cell, 

integrates into the cellular genome and 

can (1) rapidly undergo lytic infection, 

or (2) lay dormant for a period of time 

(latent infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since farnesyl 

transferase inhibitors can activate lytic 

replication from latent infected cells by 

modulating membrane-bound Ras–Rho 

levels, farnesyl transferase inhibitors 

may lead to therapies in which farnesyl 

transferase inhibitor is given together 

with highly active antiretroviral therapy 

in an effort to decrease or eliminate the 

reservoir of latent infected cells with 

hope of perhaps eventually curing a 

patient of HIV infection.

Dated: October 15, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–23650 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel. Member 

Conflict Meeting. 

Date: November 17, 2004. 

Time: 6 p.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Mark Swieter, PhD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

National Institutes of Health, DHHS, 6101 

Executive Boulevard, Suite 220, Bethesda, 

MD 20892–8401, (301) 435–1389.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23654 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting.